Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022-Reference-Cited by-同舟云学术

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

Published:2023-05 Issue: Volume:130 Page:182-188
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Veneti Lamprini^ORCID,Berild Jacob Dag,Watle Sara Viksmoen,Starrfelt Jostein^ORCID,Greve-Isdahl Margrethe,Langlete Petter,Bøås Håkon^ORCID,Bragstad Karoline,Hungnes Olav,Meijerink Hinta

Funder

Norwegian Institute of Public Health

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. Assessment of 135 794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States;Bailey;JAMA Pediatr,2021

2. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study;Götzinger;Lancet Child Adolesc Health,2020

3. Risk of adverse events after Covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study;Kildegaard;BMJ,2022

4. Covid-19: keeping schools as safe as possible;Fontanet;BMJ,2021

5. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents;Ali;N Engl J Med,2021

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence;Infectious Disorders - Drug Targets;2024-11

2. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies;International Journal of Molecular Sciences;2024-07-26

3. Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: A systematic review and meta-analysis;Medicine;2024-02-16

4. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19;Microbial Cell Factories;2024-02-06

5. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022;BMC Public Health;2024-01-15